- Home
- Equities - Stocks - Shares
- Company Press Releases
- BerGenBio To Present At DNB's Nordic Healthcare Conference
BerGenBio to present at DNB's Nordic Healthcare Conference
08 Dec 2022 07:00 CET
BERGEN, Norway, December 8, 2022 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced that Martin Olin, Chief Executive
Officer of BerGenBio, will present at the 13th Annual DNB Nordic Healthcare
Conference in Oslo, Norway, on Thursday, December 15, 2022, at 11:45am CET.
The presentation will be made available on the Company website in the
presentations section on the day of the event:
www.bergenbio.com/investors/presentations/
-End-
Contacts
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Investor Relations / Media Relations
Graham Morrell
graham.morrell@bergenbio.com
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visitwww.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
More information:
Access the news on Oslo Bors NewsWeb site
Source
BerGenBio ASA
Provider
Oslo Børs Newspoint
Company Name
BERGENBIO
ISIN
NO0010650013, NO0013251173
Symbol
BGBIO
Market
Oslo Børs